Breast brachytherapy review defines practical standards for APBI delivery
Successful breast brachytherapy depends on careful patient selection, suitable cavity anatomy, sound implant geometry, accurate reconstruction, and rigorous treatment QA.
Successful breast brachytherapy depends on careful patient selection, suitable cavity anatomy, sound implant geometry, accurate reconstruction, and rigorous treatment QA.
Higher vaginal D2cc and target-dose distribution independently predicted grade 1–2 vaginal toxicity after combined external-beam radiotherapy and cuff brachytherapy.
Millimeter-scale localization uncertainty shifted assigned biopsy doses by several Gy and made nominal DVH threshold classification frequently unreliable.
EQD2 should remain the reporting standard, but delivery time, dose gradients, biological assumptions and dose accumulation materially affect its interpretation.
High-dose-rate brachytherapy using 13.5 Gy twice achieved 81.6% ten-year biochemical control with limited late genitourinary toxicity.
Pulmonary consolidation was common after single-fraction interstitial brachytherapy and frequently evolved into progressive retraction during the second year.
High-dose-rate brachytherapy monotherapy achieved 86% biochemical control at median 13-year follow-up in localized prostate cancer.
Same-day hyaluronic acid rectal spacer placement reduced rectal dose while preserving ultrasound-based prostate brachytherapy planning.
A 3D-printed jig delivered approximately uniform iridium-192 tumor dose, delayed tumor growth, and caused no observable short-term radiation toxicity in mice.